Abstract: A exhausted-tobacco tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and exhausted-tobacco is dispersed in the solid solution, and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an adult tobacco consumer's oral cavity.

Abstract: The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.

Abstract: A nicotine tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and nicotine or a derivative thereof dispersed in the solid solution such that the nicotine or derivative thereof is released from the tablet when the tablet is chewed or dissolved within an oral cavity.

Abstract: Disclosed is a method for preparing high-load oral paclitaxel capsule for a slow release in colon, belonging to the field of porous starch drug loading. The preparation method of the present disclosure includes the following steps: (1) dripping an ethanol solution of paclitaxel into a water phase and drying the solution to obtain an amorphous paclitaxel microsphere; (2) redissolving the paclitaxel microsphere prepared in step (1) in the ethanol solution, dispersing porous starch in the ethanol solution for adsorption, volatilizing a solvent in an oven, washing the porous starch with the ethanol solution to remove unadsorbed paclitaxel, and centrifuging same to obtain a precipitate, namely the porous starch loaded with paclitaxel; and (3) dispersing the porous starch loaded with paclitaxel prepared in step (2) in a chitosan solution, dropwise adding the solution into a phytic acid solution, and stirring the solution for 4 hours to obtain a coated capsule.

Abstract: A process is provided for encapsulating glutathione (GSH), 3,3?-diindolylmethane (DIM), coenzyme-Q10 (CoQ10), and other hydrophobic antioxidant compounds by using whey proteins which may be polymerized in a particular manner. Further, compositions comprising polymerized whey protein (PWP) encapsulated glutathione, polymerized whey protein (PWP) encapsulated CoQ10, and polymerized whey protein (PWP) encapsulated DIM are provided.

Abstract: Disclosed herein are methods of improving skin appearance associated with skin aging. The method comprises the step of applying an anti-aging bioactive composition to a skin surface having at least one sign of aging. The anti-aging bioactive composition is applied for a period of time sufficient to improve the appearance of the at least one sign of aging. In one embodiment, the anti-aging bioactive composition comprises an effective amount of a Nelumbo nucifera (Sacred Lotus) serum fraction. In another embodiment, the anti-aging bioactive composition comprises an effective amount of a Chamomilla recutita (German Chamomile) Flower serum fraction. In other embodiments, the anti-aging bioactive composition can further include a dermatologically acceptable carrier.

Abstract: An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

Abstract: The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

Abstract: Disclosed herein is an analgesic solution for the treatment of pain comprising a pain-relieving effective amount of tramadol or a pharmaceutically acceptable salt thereof, a method of treating pain by administering said analgesic solution to a subject in need thereof, a kit that includes containers of the analgesic solution, and a dosing regimen for the analgesic solution.

Abstract: A powder preparation for nasal administration containing a particulate of steroid hormones having an average particle size of 50 to 300 ?m as an active ingredient is prepared.

Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described.

Abstract: Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.

Abstract: A hydrogen-containing composition for ingestion or topical use and method of producing the hydrogen-containing composition are provided. The composition includes a carrier liquid and molecular hydrogen. The concentration of molecular hydrogen in the carrier liquid is greater than 3 ppm.

Abstract: Kombucha tea faces many challenges concerning its use for its health benefits, such as standardization, as well as the determination of a specific dosage form appropriate to the intended use. Kombucha tea, as a fermented, alcohol-containing beverage that relies on a complex combination of living yeast and bacteria for production, is especially difficult to administer. The present invention provides a consistent, standardized dosage form and novel combinations of a traditional medicinal drink that is otherwise unsuitable for widespread natural medicine. By providing kombucha as a soft, chewable and orally dissolvable and/or disintegrable compositions, such as a gummie, a gummie with probiotics, or a gummy made from tapioca syrup, a unique, desirable flavor and mouthfeel is obtained and which is also alcohol free. This expands the number of people who can enjoy the benefits of the traditional tea.

Abstract: A series of particles, in which each particle contains at least 3 wt. % of pigment(s) in relation to the weight of the particle, a method for producing the series of particles, and uses thereof in cosmetic compositions, particularly in make-up for keratinous materials.

Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Abstract: An injectable pharmaceutical formulation includes nanofibrillar cellulose hydrogel wherein the content of nanofibrillar cellulose in the pharmaceutical formulation is the range of 1-8% (w/w), and pharmaceutical compound. The injectable pharmaceutical formulation can provide a sustained release of a pharmaceutical compound in a subject. Use of nanofibrillar cellulose for preparing the injectable pharmaceutical formulation is also disclosed.

Abstract: Disclosed herein are exemplary medical devices for controlled delivery of material compositions, particularly occlusive, therapeutic, or diagnostic compositions.

Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.